SGCM
AUTL

Sand Grove Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Sand Grove Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-103,718
Closed -$1.63M – 13
2019
Q2 		$1.63M Buy
+103,718
New +$2.32M 0.17% 14

Other funds holding AUTL

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Sand Grove Capital Management's AUTL Position: Q3 2019 in Review

Sand Grove Capital Management sold out of Autolus Therapeutics (AUTL) in Q3 2019, closing a stake of 103,718 shares — an estimated $1.63M sold.

Sand Grove Capital Management first reported a position in AUTL in Q2 2019 and held it in 1 quarter. The position peaked at $1.63M in Q2 2019. 43 funds tracked by Wall St. Rank hold AUTL as of Q3 2019.

  • Sand Grove Capital Management reported no remaining Autolus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Sand Grove Capital Management sold 103,718 Autolus Therapeutics shares in Q3 2019, an estimated $1.63M.
  • Sand Grove Capital Management first reported a position in Autolus Therapeutics in Q2 2019 and held it in 1 quarter.
  • Sand Grove Capital Management's Autolus Therapeutics position peaked at $1.63M in Q2 2019.
  • 43 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2019.

Based on Sand Grove Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.